All In Biotech

Drug Trial Radar · NCT03277690

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Sep 26, 2017

Primary completion

Jun 30, 2020

Study completion Aug 31, 2020

Sponsor

Lead sponsor
Cortendo ABIndustry
Sponsor type
Industry
First posted
Sep 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of levoketoconazole.

Conditions

  • Endogenous Cushing's Syndrome

Interventions

  • LevoketoconazoleDrug

    During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily. During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo.

  • PlaceboDrug

    During the double-blind Withdrawal Phase, patients will receive placebo tablets. During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic Response Upon Continuing Treatment With Levoketoconazole.Time frame: max. 9.5 weeks

Locations

45 sites in 12 countries. Site status is shown where the registry gives one.

  • Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital

    Los Angeles, California

  • Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center

    Los Angeles, California

  • UCLA School of Medicine, Medicine/Endocrinology Department

    Los Angeles, California

  • The Center for Diabetes and Endocrine Care

    Fort Lauderdale, Florida

  • Emory University, Neurosurgery

    Atlanta, Georgia

  • Northwestern University, Medicine - Endocrinology

    Chicago, Illinois

  • Johns Hopkins University, Endocrinology Department

    Baltimore, Maryland

  • University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND

    Ann Arbor, Michigan

  • Washington University School of Medicine, Endocrinology

    St Louis, Missouri

  • Columbia University, College of P&S Medicine/Neuro-endocrine Unit

    New York, New York

  • Memorial Sloan Kettering Cancer Center, Endocrinology

    New York, New York

  • Oregon Health & Science University, Neurological Surgery

    Portland, Oregon

  • Allegheny Neuroendocrinology Center, West Penn Allegheny Health System

    Pittsburgh, Pennsylvania

  • Alexandovska University Hospital, Clinic of Endocrinology & Metabolic Diseases

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD Clinic of Endocrinology and Metabolic Diseases

    Sofia, Bulgaria

  • University Specialized Hospital for Active Treatment in Endocrinology (USHATE) I Klinika

    Sofia, Bulgaria

  • Rigshospitalet, Copenhagen University Hospital, Endocrinology Department

    Copenhagen, Denmark

  • APHM Hôpital de la Conception, Service d'Endocrinologie, Diabète et Maladies Métaboliques

    Marseille, Cedex 5, France

  • Evangelismos Athens General Hospital, Department of Endocrinology

    Athens, Greece

  • General Hospital of Athens 'G. Gennimatas', Department of Endocrinology-Diabetes Centre

    Athens, Greece

  • General Hospital of Athens 'Laiko', "National and Kapodistrian University of Athens Medical School Pathophysiology - Endocrinology"

    Athens, Greece

  • University General Hospital of Ioannina, Department of Endocrinology

    Ioannina, Greece

  • Hippokration General Hospital, "Endocrinology and Diabetes Department

    Thessaloniki, Greece

  • Semmelweis Egyetem II. Belgyógyászati Klinika A.épület I.emelet ODM-labor

    Budapest, Hungary

  • Bnai Zion Medical Center, Institute of Endocrinology

    Haifa, Israel

  • Rabin Medical Center- Beilinson Hospital, "Institute of Endocrinology & Metabolism, Beilinson Campus"

    Petah Tikva, Israel

  • Tel-Aviv Sourasky Medical Center Institute of Endocrinology, Metabolism and Hypertension

    Tel Aviv, Israel

  • Clinica di Endocrinologia e malattie del Metabolismo, Dipartimento Specialità Mediche

    Ancona, Italy

  • University of Genova, Department of Internal Medicine & Medical Specialties (DiMI)

    Genova, Italy

  • AOU Policlinico G. Martino Sezione di Endocrinologia

    Messina, Italy

  • AOU Federico II, Sezione di Endocrinologia (Edificio 1, Secondo Piano)

    Naples, Italy

  • Policlinico Agostino Gemelli, Università Cattolica del Sacro Cuore, Endocrinology

    Roma, Italy

  • Policlinico Universitario Sant'Andrea, Scienze Mediche

    Roma, Italy

  • AOU Citta della Salure e della Scienza SC Endocrinologia, Diabetologia e Metabolismo

    Torino, Italy

  • Leiden University, Leiden University Medical Center, Department of Endocrinology

    Leiden, Netherlands

  • Erasmus Medical Center, Department of Internal Medicine

    Rotterdam, Netherlands

  • Maria Sklodowska-Curie Memorial Institute - Cancer Center Gliwice Branch, Nuclear Medicine and Endocrine Oncology Department

    Gliwice, Poland

  • Instytut Centrum Zdrowia Matki Polki, Oddział Endokrynologii i Chorób Metabolicznych

    Lodz, Poland

  • Wojskowy Instytut Medyczny, Klinika Gastroenterologii, Endokrynologii I Chorob Wewnetrznych

    Warsaw, Poland

  • Institutul National de Endocrinologie C.I. Parhon, Sectia Clinica de Endocrinologie II, Patologia tiroidei de corelatie

    Bucharest, Romania

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.